Rapid Enrollment and Dosing of First Patients Encouraging and Underscores Unmet Need for Better Treatment Options for Alzheimer’s Disease ...

Objective: The aim of the present study was to monitor the efficacy and tolerability of glimepiride in daily practice. Design: An 8-week non-interventional cohort study investigating glimepiride ...

has proven efficacy and tolerability in migraine. In a prospective open-label study, Lampl and co-workers have shown this drug to have promise in the prophlyaxis of chronic tension-type headache.

Inceptor Bio, a clinical-stage biotechnology company pioneering next-generation cell therapies, today announced that the first patient has been dosed in the clinical trial of IB-T101, the company's ...

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, ...

During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...

Preclinical in vivo data show that OKI-219 used in combination with standard-of-care therapies for mutant-selected solid tumors, including breast cancers, showed potent anti-tumor activity with ...

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

A PDUFA date has been set for October 20, 2025. If approved, Epoxia will be the first epi-on corneal crosslinking on the market.

Boehringer Ingelheim, the UK Respiratory Gene Therapy Consortium (GTC), IP Group and Oxford BioMedica (OXB) have commenced ...